Grade 3-5 adverse events were comparable between both treatment groups. Evidence Rating Level: 1 (Excellent) Study Rundown: ...

Kineta has completed enrollment in the monotherapy cohorts of the Phase 1 VISTA-101 clinical trial. The ongoing Phase 1 study is now enrolling patients into cohorts evaluating KVA12123 in combination ...

Astellas Pharma Ltd. today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted authorization for PADCEV™ (enfortumab vedotin, an antibody-drug conjugate [ADC]) in ...

In the randomized, double-blind, phase 3 study, experts explored treatment with neoadjuvant pembrolizumab (Keytruda) plus chemotherapy, followed by adjuvant pembrolizumab, in patients aged 18 years ...

This study is looking at an immunotherapy treatment called V940 (mRNA-4157) with pembrolizumab to treat melanoma.

Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in ...

A humanised monoclonal antibody, KEYTRUDA can enhance the immune system's potential to detect and combat tumour cells.

New Delhi: For nearly a decade, pembrolizumab—sold under the brand name Keytruda—has dominated the cancer immunotherapy ...

The imaging agent Gleolan is only approved for glioma surgery, so the current trial could lead to a new indication. In this ...

The KEYNOTE-689 study evaluating pembrolizumab in this patient population met its primary end point of event-free survival.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

“Based on our strong phase 2 clinical data reported previously for petosemtamab in HNSCC both as monotherapy and in combination with pembrolizumab, I continue to be confident that petosemtamab ...